Pioglitazone (Actos) — Thiazolidinedione Insulin Sensitizer — Weight & Metabolism
FDA-approved PPAR-gamma agonist for type 2 diabetes. Improves insulin sensitivity but carries bladder cancer and weight gain warnings.
Overview
Pioglitazone (Actos) is a thiazolidinedione (TZD) insulin sensitizer that activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor predominantly expressed in adipose tissue. FDA-approved in 1999 for type 2 diabetes, pioglitazone improves insulin sensitivity by promoting adipogenesis (differentiation of preadipocytes into mature adipocytes), enhancing glucose uptake in skeletal muscle, and reducing hepatic glucose output. Unlike metformin, pioglitazone uniquely improves insulin sensitivity at the level of the adipocyte, promoting subcutaneous fat storage over visceral and ectopic fat deposition. The PROactive trial demonstrated cardiovascular benefits, with a 16% reduction in the composite secondary endpoint of all-cause mortality, MI, and stroke. Pioglitazone also shows promise for NASH, with multiple studies demonstrating improvement in liver histology, fibrosis, and transaminases. However, pioglitazone carries significant safety concerns: weight gain (2-5 kg due to fluid retention and fat redistribution), increased fracture risk (particularly in postmenopausal women), and an FDA boxed warning regarding a possible association with bladder cancer. The bladder cancer signal remains debated — some studies confirm a modest association with prolonged use (>2 years), while others find no significant risk.
Indications
- FDA-approved: Type 2 diabetes mellitus (monotherapy or combination)
- Off-label: NASH/MASH (liver fibrosis improvement)
- Off-label: Polycystic ovary syndrome (PCOS)
- Off-label: Lipodystrophy syndromes
Mechanism of Action
Pioglitazone binds and activates PPAR-gamma nuclear receptors in adipose tissue, modulating transcription of insulin-responsive genes
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Pioglitazone (Actos) | 15 mg | Once daily | Starting dose |
| Pioglitazone | 30 mg | Once daily | Standard maintenance dose |
| Pioglitazone | 45 mg | Once daily | Maximum dose |
Evidence Grade
GRADE A
Safety & Contraindications
- Weight gain (2-5 kg) from fluid retention and adipogenesis
- Peripheral edema and potential for heart failure exacerbation — contraindicated in NYHA Class III/IV HF
- FDA boxed warning: possible increased bladder cancer risk with prolonged use
- Increased fracture risk in women (distal long bones)
- Hepatotoxicity (rare) — check LFTs before and periodically
- Macular edema (rare)
- Takes 2-3 months for full effect on glycemic control